ALMS: KOL Commentary Supports Our High POS View on Envu's LUMUS SLE Ph2b; Reiterate Overweight

Research evidence excerpt

ALMS: KOL Commentary Supports Our High POS View on Envu's LUMUS SLE Ph2b; Reiterate Overweight

Alumis Inc. Equity Research

Our KOL Described the Current Treatment Algorithm in Lupus

Dr. Geraldino-Pardilla discussed her current practice. Our KOL practices at a tertiary academic center

with a dedicated lupus center that has followed approximately 400–450 lupus patients annually for

nearly two decades. Based in an underserved area of New York City, the clinic's population is ~65%

Black or Hispanic, providing significant exposure to patients with earlier-onset, more severe, and

treatment-refractory disease. The center is actively involved in multiple lupus clinical trials, often

offering investigational options after approved therapies have been exhausted. Care is delivered

through a multidisciplinary model with close collaboration between rheumatology, dermatology,

and nephrology, and the center also operates a transition clinic for childhood-onset lupus patients, a

smaller but particularly complex subset of the population.

The KOL noted that lupus treatment has traditionally been divided into two broad categories:

active lupus nephritis (LN) and non-renal moderate-to-severe SLE, a framework that has shaped

both clinical practice and trial design. Hydroxychloroquine (anti-malaria treatment) remains the

universal foundation of lupus treatment, but growing pipeline activity is prompting questions about

whether earlier use of additional therapies could improve outcomes. For lupus nephritis, treatment

is increasingly standardized around aggressive upfront triple therapy consisting of MMF, steroids,

and a third agent such as a B-cell depleting therapy (even though guidelines say bortezomib or

pomalidomide), with obinutuzumab expected to further reshape the treatment paradigm.